CHILD-INNOVAC is a European
research network (Collaborative Project) coordinated by the French
Institute of Health and Medical Research (Inserm, Dr. Camille Locht, Lille - FRANCE) and supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme.
To download Child-Innovac presentation leaflet, please clickhere.
The Child-Innovac Newsletter presenting the latest progresses of the Network and the main event in the feild is available here .
At the end of its first year
of activity, the Child-Innovac consortium has achieved major progresses towards its goals. To know more about Child-Innovac, please visit "Our activities" page.
Context
Despite the great advances in the prevention and treatment of infectious diseases, respiratory infections remain the most frequent cause of childhood morbidity and mortality worldwide. Although licensed vaccines targeting several of these diseases exist and are widely used, respiratory pathogens still cause more than four million deaths per year. Most of these deaths occur in young children. For many respiratory pathogens no satisfactory vaccine is available. For others, classical parenteral immunisation remains insufficiently effective.
Click here to view some interesting video on B.pertussis
New:publish your job offers and job search on Child-Innovac website
French student looking for an internship in biochemistry and molecular biology in Europe - see C.V. here
Meet us at ECCMID 21st symposium in Milano (Italy)
The Child-Innovac project, participants and achievements will be presented on a poster at the "European Networks Corner" of the 21st ECCMID symposium .
The Swedish Medicines Product Agency and the Swedish Ethical Committee have approved the Phase I trialin August 2010
This Phase I is aiming at prooving the safety of the BPZE 1 vaccine in healthy volunteers.
The BPZE 1 vaccine has been proven to be safe and well tolerated in mice
The toxicological studies conducted in May-October 2009 have proven
that the BPZE 1 vaccine was safe and well tolerated in mice, even after repeated administration.Toxicology studies have been performed by the swedish CRO VISIONAR PRECLINIAL.
December 2009: INSERM is the sponsor the Phase 1 safety trial to be launched in Sweden during summer 2010. This multinational clinical trial will be benefit from ECRIN support, the European Clinical Research Infrastructures Network.
